Cargando…
Development and Validation of a Dried Blood Spot Assay Using UHPLC-MS/MS to Identify and Quantify 12 Antihypertensive Drugs and 4 Active Metabolites: Clinical Needs and Analytical Limitations
As nonadherence to antihypertensive drugs (AHDs) can increase the risk of cardiovascular events, hospitalization, and higher costs, there is a need for a reliable, objective, and easy method to assess nonadherence in patients. The dried blood spot (DBS) sampling method used to measure drug concentra...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Therapeutic Drug Monitoring
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275854/ https://www.ncbi.nlm.nih.gov/pubmed/35383727 http://dx.doi.org/10.1097/FTD.0000000000000984 |
_version_ | 1784745578427580416 |
---|---|
author | Peeters, Laura E. J. Bahmany, Soma Dekker, Tim Aliawi, Aya van Domburg, Bart Versmissen, Jorie Koch, Birgit C. P. |
author_facet | Peeters, Laura E. J. Bahmany, Soma Dekker, Tim Aliawi, Aya van Domburg, Bart Versmissen, Jorie Koch, Birgit C. P. |
author_sort | Peeters, Laura E. J. |
collection | PubMed |
description | As nonadherence to antihypertensive drugs (AHDs) can increase the risk of cardiovascular events, hospitalization, and higher costs, there is a need for a reliable, objective, and easy method to assess nonadherence in patients. The dried blood spot (DBS) sampling method used to measure drug concentrations meets these requirements. For detecting nonadherence, identification is more important than quantification. Owing to their use in clinical practice, it is important to measure multiple AHDs with a single method. Therefore, we developed and validated a single DBS method for 17 commonly used AHDs and 4 active metabolites using ultrahigh performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS). METHODS: Analytical validation of the DBS assay was performed in accordance with the guidelines on bioanalytical method validation of the European Medicines Agency and US Food and Drug Administration as well as the International Association of Therapeutic Drug Monitoring and Clinical Toxicology guidelines. RESULTS: We validated 12 of the 17 AHDs according to the European Medicines Agency and Food and Drug Administration requirements for bioanalytical method validation. Eleven AHDs were validated for both identification and quantification of drug concentrations, whereas nifedipine was only validated for identification. However, 5 of the 17 AHDs were excluded due to suboptimal validation results. Lercanidipine was excluded due to nonlinearity, and all 4 AHDs measured in the negative mode of UHPLC-MS/MS were not in accordance with one or more of the acceptance criteria and were therefore excluded. CONCLUSIONS: The described method accurately measured AHDs in DBS and can be used to determine nonadherence in patients. However, method validation revealed a challenging balance between analytical limitations and clinical needs when analyzing multiple drugs using the same method. |
format | Online Article Text |
id | pubmed-9275854 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Therapeutic Drug Monitoring |
record_format | MEDLINE/PubMed |
spelling | pubmed-92758542022-08-02 Development and Validation of a Dried Blood Spot Assay Using UHPLC-MS/MS to Identify and Quantify 12 Antihypertensive Drugs and 4 Active Metabolites: Clinical Needs and Analytical Limitations Peeters, Laura E. J. Bahmany, Soma Dekker, Tim Aliawi, Aya van Domburg, Bart Versmissen, Jorie Koch, Birgit C. P. Ther Drug Monit Original Article As nonadherence to antihypertensive drugs (AHDs) can increase the risk of cardiovascular events, hospitalization, and higher costs, there is a need for a reliable, objective, and easy method to assess nonadherence in patients. The dried blood spot (DBS) sampling method used to measure drug concentrations meets these requirements. For detecting nonadherence, identification is more important than quantification. Owing to their use in clinical practice, it is important to measure multiple AHDs with a single method. Therefore, we developed and validated a single DBS method for 17 commonly used AHDs and 4 active metabolites using ultrahigh performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS). METHODS: Analytical validation of the DBS assay was performed in accordance with the guidelines on bioanalytical method validation of the European Medicines Agency and US Food and Drug Administration as well as the International Association of Therapeutic Drug Monitoring and Clinical Toxicology guidelines. RESULTS: We validated 12 of the 17 AHDs according to the European Medicines Agency and Food and Drug Administration requirements for bioanalytical method validation. Eleven AHDs were validated for both identification and quantification of drug concentrations, whereas nifedipine was only validated for identification. However, 5 of the 17 AHDs were excluded due to suboptimal validation results. Lercanidipine was excluded due to nonlinearity, and all 4 AHDs measured in the negative mode of UHPLC-MS/MS were not in accordance with one or more of the acceptance criteria and were therefore excluded. CONCLUSIONS: The described method accurately measured AHDs in DBS and can be used to determine nonadherence in patients. However, method validation revealed a challenging balance between analytical limitations and clinical needs when analyzing multiple drugs using the same method. Therapeutic Drug Monitoring 2022-08 2022-04-05 /pmc/articles/PMC9275854/ /pubmed/35383727 http://dx.doi.org/10.1097/FTD.0000000000000984 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Peeters, Laura E. J. Bahmany, Soma Dekker, Tim Aliawi, Aya van Domburg, Bart Versmissen, Jorie Koch, Birgit C. P. Development and Validation of a Dried Blood Spot Assay Using UHPLC-MS/MS to Identify and Quantify 12 Antihypertensive Drugs and 4 Active Metabolites: Clinical Needs and Analytical Limitations |
title | Development and Validation of a Dried Blood Spot Assay Using UHPLC-MS/MS to Identify and Quantify 12 Antihypertensive Drugs and 4 Active Metabolites: Clinical Needs and Analytical Limitations |
title_full | Development and Validation of a Dried Blood Spot Assay Using UHPLC-MS/MS to Identify and Quantify 12 Antihypertensive Drugs and 4 Active Metabolites: Clinical Needs and Analytical Limitations |
title_fullStr | Development and Validation of a Dried Blood Spot Assay Using UHPLC-MS/MS to Identify and Quantify 12 Antihypertensive Drugs and 4 Active Metabolites: Clinical Needs and Analytical Limitations |
title_full_unstemmed | Development and Validation of a Dried Blood Spot Assay Using UHPLC-MS/MS to Identify and Quantify 12 Antihypertensive Drugs and 4 Active Metabolites: Clinical Needs and Analytical Limitations |
title_short | Development and Validation of a Dried Blood Spot Assay Using UHPLC-MS/MS to Identify and Quantify 12 Antihypertensive Drugs and 4 Active Metabolites: Clinical Needs and Analytical Limitations |
title_sort | development and validation of a dried blood spot assay using uhplc-ms/ms to identify and quantify 12 antihypertensive drugs and 4 active metabolites: clinical needs and analytical limitations |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275854/ https://www.ncbi.nlm.nih.gov/pubmed/35383727 http://dx.doi.org/10.1097/FTD.0000000000000984 |
work_keys_str_mv | AT peeterslauraej developmentandvalidationofadriedbloodspotassayusinguhplcmsmstoidentifyandquantify12antihypertensivedrugsand4activemetabolitesclinicalneedsandanalyticallimitations AT bahmanysoma developmentandvalidationofadriedbloodspotassayusinguhplcmsmstoidentifyandquantify12antihypertensivedrugsand4activemetabolitesclinicalneedsandanalyticallimitations AT dekkertim developmentandvalidationofadriedbloodspotassayusinguhplcmsmstoidentifyandquantify12antihypertensivedrugsand4activemetabolitesclinicalneedsandanalyticallimitations AT aliawiaya developmentandvalidationofadriedbloodspotassayusinguhplcmsmstoidentifyandquantify12antihypertensivedrugsand4activemetabolitesclinicalneedsandanalyticallimitations AT vandomburgbart developmentandvalidationofadriedbloodspotassayusinguhplcmsmstoidentifyandquantify12antihypertensivedrugsand4activemetabolitesclinicalneedsandanalyticallimitations AT versmissenjorie developmentandvalidationofadriedbloodspotassayusinguhplcmsmstoidentifyandquantify12antihypertensivedrugsand4activemetabolitesclinicalneedsandanalyticallimitations AT kochbirgitcp developmentandvalidationofadriedbloodspotassayusinguhplcmsmstoidentifyandquantify12antihypertensivedrugsand4activemetabolitesclinicalneedsandanalyticallimitations |